Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 225

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 8
Chunk 225
---
creating market demand for such products through marketing, sales and promotion activities; 

■hiring, training, and deploying a sales force or contracting with third parties to commercialize such products in the United States; 

■creating strategic collaborations with, or offering licenses to, third parties to promote and sell such products in foreign markets where we receive marketing approval; 

■manufacturing such products in sufficient quantities and at acceptable quality and cost to meet commercial demand at launch and thereafter; 

■establishing and maintaining agreements with wholesalers, distributors, and group purchasing organizations on commercially reasonable terms; 

■maintaining patent and trade secret protection and regulatory exclusivity for such products; 

■achieving market acceptance of such products by patients, the medical community, and third-party payors; 

■achieving coverage and adequate reimbursement from third-party payors for such products; 

■patients’ willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement from third-party payors; 

■effectively competing with other therapies; and 

■maintaining a continued acceptable safety profile of such products following launch. 

To the extent we are not able to do any of the foregoing, our business, financial condition, results of operations, stock price and prospects will be materially harmed. 

We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and 

46

well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring